HR Execs on the Move


 
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.vical.com
  • 10390 Pacific Center Ct
    San Diego, CA USA 92121
  • Phone: 858.646.1100

Executives

Name Title Contact Details

Similar Companies

Allergy Associates Medical Group

Allergy Associates Medical Group is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sutro Biopharma

At Sutro Biopharma, a clinical stage company, we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer therapeutics and autoimmune disease — Antibody Conjugates, Bispecific Antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.

Rimsys Regulatory Management Software

Learn about the first and only holistic Regulatory Information Management (RIM) software for medical device companies that consolidates all the functions of regulatory affairs.

WRS

Aspyrian Therapeutics

Aspyrian Therapeutics is a new start-up located in San Diego (California, USA) that focuses on developing novel targeted therapies for Oncology, Inflammation, and Pain. Aspyrian Therapeutics and its collaborators are developing novel cancer targeted therapies based on proprietary technologies that achieve highly specific and tumor restricted anticancer activity. Tumor specific action serves to avoid damage to healthy organs for enhanced anticancer activity and increased safety profile. Aspyrian Therapeutics has secured the exclusive license from the National Cancer Institute for a new Antibody Conjugate Technology: Near-infrared Photoimmunotherapy (PIT). PIT permits highly efficient and selective ablation of tumor cells while sparing damage to critical structures adjacent to the tumor.